EUVIMEDEUVIMED entdecken
Crossref

Expression of STAT ‐ and T‐cell‐related genes in women with first‐line treatment of relapsing‐remitting multiple sclerosis

Ludmiła Szewczak iD, Maja Machcińska, Magdalena Kierasińska, Urszula Zawadzka-Więch, Marta Maruszewska-Cheruiyot, Paweł Majewski, Anna Karlińska, Rafał Rola, Katarzyna Donskow-Łysoniewska

Scandinavian Journal of Immunology · 2025

DOI: 10.1111/sji.13424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scandinavian Journal of Immunology, 2025. Verfasst von Ludmiła Szewczak und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Parasitology, General Karol Kaczkowski Military Institute of Hygiene and Epidemiology, Warsaw, Poland. Hauptthemen laut MEDLINE: Multiple Sclerosis, Relapsing-Remitting, T-Lymphocytes, Dimethyl Fumarate, Interferon-beta. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Fundacja na rzecz Nauki Polskiej.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapsing‐remitting multiple sclerosis is associated with changes in Jak/STAT pathways in immune cells, but the influence of disease‐modifying drugs on these pathways is poorly understood. The aim of this study was to evaluate the impact of first‐line disease‐modifying drugs used in treatment of RRMS on expression of the STAT pathway and T‐cell‐related genes in the blood and on serum concentrations of sgp130 and TGF‐β1 in women, as well as on the level of phosphorylated STAT3 and STAT5 proteins in T cells of untreated patients and heathy controls. Expression of STAT1 , STAT3 , STAT5A , STAT5B , SOCS1 , SOCS3 , FOXP3 , IKZF2 , RORC and ICOS genes in the blood of untreated RRMS patients, in the blood of patients treated with interferon‐β, glatiramer acetate, dimethyl fumarate or teriflunomide and in the blood of healthy controls was evaluated using droplet digital PCR. Serum concentrations of sgp130 and TGF‐β1 were evaluated by ELISA. Phosphorylated STAT3 and STAT5 protein levels in T cells were evaluated by flow cytometry. STAT3 gene expression was significantly higher in untreated patients than in healthy control, but the level of phosphorylated STAT3 in T cells was significantly lower. Patients treated with interferon‐β or dimethyl fumarate had significantly lower STAT3 gene expression. Patients treated with teriflunomide had higher STAT1 gene expression, than untreated patients. Patients treated with dimethyl fumarate also had significantly lower RORC gene expression than untreated patients. The study shows the impact of drugs used in first‐line treatment of relapsing‐remitting multiple sclerosis on expression of STAT and T‐cell‐related genes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Sclerosis, Relapsing-RemittingT-LymphocytesDimethyl FumarateInterferon-betaHumansFemaleAdultTransforming Growth Factor beta1STAT3 Transcription FactorMiddle AgedNitrilesToluidinesGlatiramer AcetateHydroxybutyratesSTAT5 Transcription FactorNuclear Receptor Subfamily 1, Group F, Member 3Inducible T-Cell Co-Stimulator ProteinPhosphorylationSuppressor of Cytokine Signaling 1 ProteinYoung AdultSignal TransductionSTAT1 Transcription FactorGene Expression RegulationCrotonates

Stichwörter der Autor:innen

Disease‐modifying drugsSTAT transcription factorsT cellrelapsing‐remitting multiple sclerosis

Substanzen

Dimethyl FumarateInterferon-betaTransforming Growth Factor beta1STAT3 Transcription FactorNitrilesToluidinesRORC protein, humanGlatiramer AcetateteriflunomideHydroxybutyrates

Autor:innen und Institutionen

  • Laboratory of Parasitology, General Karol Kaczkowski Military Institute of Hygiene and Epidemiology, Warsaw, Poland.
  • Department of Histology and Embryology, Medical University of Warsaw, Warsaw, Poland.
  • Department of Animal Physiology, Institute of Experimental Zoology, Faculty of Biology, University of Warsaw, Warsaw, Poland.
  • Department of Experimental Immunotherapy, Faculty of Medicine, Lazarski University, Warsaw, Poland.
  • Department of Neurology, Military Institute of Aviation Medicine, Warsaw, Poland.

ORCID-Profile: Ludmiła Szewczak

Förderung

  • Fundacja na rzecz Nauki Polskiej

Zitieren

APA

Szewczak, L., Machcińska, M., Kierasińska, M., Zawadzka-Więch, U., Maruszewska-Cheruiyot, M., Majewski, P., Karlińska, A., Rola, R., & Donskow-Łysoniewska, K. (2025). Expression of STAT ‐ and T‐cell‐related genes in women with first‐line treatment of relapsing‐remitting multiple sclerosis. Scandinavian Journal of Immunology. https://doi.org/10.1111/sji.13424

Vancouver

Szewczak L, Machcińska M, Kierasińska M, Zawadzka-Więch U, Maruszewska-Cheruiyot M, Majewski P, et al. Expression of STAT ‐ and T‐cell‐related genes in women with first‐line treatment of relapsing‐remitting multiple sclerosis. Scandinavian Journal of Immunology. 2025. doi:10.1111/sji.13424

BibTeX
@article{Szewczak2025,
  author = {Szewczak, Ludmiła and Machcińska, Maja and Kierasińska, Magdalena and Zawadzka-Więch, Urszula and Maruszewska-Cheruiyot, Marta and Majewski, Paweł and Karlińska, Anna and Rola, Rafał and Donskow-Łysoniewska, Katarzyna},
  title = {Expression of STAT ‐ and T‐cell‐related genes in women with first‐line treatment of relapsing‐remitting multiple sclerosis},
  journal = {Scandinavian Journal of Immunology},
  year = {2025},
  doi = {10.1111/sji.13424}
}
Kostenlos starten →